Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CO
Hemab Therapeutics Holdings, Inc. Common Stock
COAG
Mkt Cap
$1.40B
Volume
268.17K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CO
COAG
CO
Hemab Therapeutics Holdings, Inc. Common Stock
COAG
News
·
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Mkt Cap
$1.52B
Volume
268.17K
Next Earnings
November 10th
Chart
Financials
Earnings
News
About
Insider
Filings
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics presented clinical data from HMB-002 showing proof of mechanism in Von Willebrand disease, with dose-dependent increases in VWF and FVIII levels supporting potential monthly subcutaneous dosing. The company also announced HMB-003, a novel non-hormonal antifibrinolytic designed to treat heavy menstrual bleeding with extended duration of action.
GlobeNewswire Inc. · Jul 12, 2026
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Hemab Therapeutics Holdings, Inc. (NASDAQ: COAG), a clinical-stage biotechnology company focused on blood coagulation disorder treatments, successfully closed its IPO on May 4, 2026. The company raised approximately $346.7 million through the sale of 19,262,500 shares at $18.00 per share, with underwriters fully exercising their option to purchase an additional 2,512,500 shares. The company's stock began trading on Nasdaq on May 1, 2026.
Benzinga · May 4, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CO
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
COAG
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any COAG yet.
Related Tickers
Earnings